Cytokinetics (CYTK) Total Non-Current Liabilities (2016 - 2025)
Historic Total Non-Current Liabilities for Cytokinetics (CYTK) over the last 9 years, with Q3 2024 value amounting to $1.4 billion.
- Cytokinetics' Total Non-Current Liabilities rose 2298.24% to $1.4 billion in Q3 2024 from the same period last year, while for Sep 2024 it was $1.4 billion, marking a year-over-year increase of 2298.24%. This contributed to the annual value of $1.2 billion for FY2023, which is 791.9% up from last year.
- Cytokinetics' Total Non-Current Liabilities amounted to $1.4 billion in Q3 2024, which was up 2298.24% from $1.4 billion recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Total Non-Current Liabilities ranged from a high of $1.4 billion in Q3 2024 and a low of $153.3 million during Q1 2020
- Its 5-year average for Total Non-Current Liabilities is $784.4 million, with a median of $736.8 million in 2022.
- Per our database at Business Quant, Cytokinetics' Total Non-Current Liabilities surged by 17016.09% in 2022 and then skyrocketed by 771.4% in 2024.
- Cytokinetics' Total Non-Current Liabilities (Quarter) stood at $420.4 million in 2020, then surged by 41.05% to $593.0 million in 2021, then skyrocketed by 89.15% to $1.1 billion in 2022, then grew by 7.92% to $1.2 billion in 2023, then rose by 19.79% to $1.4 billion in 2024.
- Its last three reported values are $1.4 billion in Q3 2024, $1.4 billion for Q2 2024, and $1.2 billion during Q1 2024.